L. Paz-Ares

Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Anne‐Marie C. Dingemans, Lizza Hendriks, Thierry Berghmans et al. · Journal of Thoracic Oncology · 2019 · 281 citations · Full text

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer et al. · Annals of Oncology · 2022 · 71 citations

Medicine, Clinical Trials, Adjuvant Chemotherapy +9

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS–RAF</i> Mutations

Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García et al. · Clinical Cancer Research · 2014 · 69 citations · Full text

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip et al. · Journal of Thoracic Oncology · 2019 · 48 citations · Full text

Advanced Nsclc, Ecog Ps 2, Therapeutic Efficacy +4

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer et al. · Annals of Oncology · 2019 · 38 citations · Full text

Neuro-oncology, Oncology, Brain Metastases +7